Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

Katrina Wilcox Hagberg,1 Rebecca Persson,1 Catherine Vasilakis-Scaramozza,1 Steve Niemcryk,2 Michael Peng,2 Maria Paris,2 Anders Lindholm,2 Susan Jick1,3 1Boston Collaborative Drug Surveillance Program, Lexington, MA 02421, USA; 2Celgene Corporation, Summit, NJ 07901, USA; 3Boston University School...

Full description

Bibliographic Details
Main Authors: Hagberg KW, Persson R, Vasilakis-Scaramozza C, Niemcryk S, Peng M, Paris M, Lindholm A, Jick S
Format: Article
Language:English
Published: Dove Medical Press 2020-02-01
Series:Clinical Epidemiology
Subjects:
apremilast
psoriasis
psoriatic arthritis
herpes zoster
hepatitis c
tuberculosis
Online Access:https://www.dovepress.com/herpes-zoster-hepatitis-c-and-tuberculosis-risk-with-apremilast-compar-peer-reviewed-article-CLEP

Internet

https://www.dovepress.com/herpes-zoster-hepatitis-c-and-tuberculosis-risk-with-apremilast-compar-peer-reviewed-article-CLEP

Similar Items